The Zhitong Finance App learned that on November 6, according to relevant market data, the Chinese herbal medicine product supplier Xinhehua (02206) is initially expected to record 59,000 subscriptions, an oversubscription of 2,192 times, and an investment of HK$72.9 billion.
New Lotus will be offering shares starting October 30. The offering price is HK$40.2 to HK$50.55 per share, 50 shares per lot, and the entry fee is HK$2552.99. Of the 6.517 million shares sold globally, 90% were international placements, and Hong Kong accounted for 10% of the shares offered, raising a maximum capital of HK$329 million. GF Securities and Agricultural Bank International are co-sponsors. The company expects to set prices on November 9, announce allotment results on November 10, and list on November 11.
According to the prospectus, New Lotus is a major supplier of traditional Chinese medicine (“TCM”) tablet products in China. According to Frost & Sullivan's data, based on revenue from Chinese herbal medicine products in 2025, New Lotus ranked 2nd in China, accounting for 0.4% of the market share in a highly competitive market pattern, while the top five market participants together held 2.7% of the market share.
On the financial side, the company recorded revenue of about 1,146 billion yuan, 1,249 billion yuan, 1,335 billion yuan, and 432 million yuan in 2023, 2024, 2025, and 2026 respectively. In the same period, the company recorded total annual revenue of about 104 million yuan, 90 million yuan, 107 million yuan, and 34 million yuan respectively.